Betta Pharmaceuticals Co Ltd (300558) — Working Capital to Net Assets Ratio
Betta Pharmaceuticals Co Ltd (300558) has a Working Capital to Net Assets ratio of -0.2% as of March 2026. Working capital of CN¥-15.94 Million (current assets of CN¥1.67 Billion minus current liabilities of CN¥1.69 Billion) is measured against net assets of CN¥6.86 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 300558 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Betta Pharmaceuticals Co Ltd Working Capital to Net Assets (2011–2025)
This chart shows how Betta Pharmaceuticals Co Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at -0.2%, reflecting working capital of CN¥-15.94 Million against net assets of CN¥6.86 Billion CNY. See defensive interval ratio of Betta Pharmaceuticals Co Ltd to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Betta Pharmaceuticals Co Ltd (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Betta Pharmaceuticals Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Betta Pharmaceuticals Co Ltd (300558) total market value.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -5.1% | CN¥-339.45 Million | CN¥6.67 Billion | CN¥1.58 Billion | CN¥1.92 Billion | ▲ +5.9 pp |
| 2024 | -11.0% | CN¥-623.63 Million | CN¥5.67 Billion | CN¥1.22 Billion | CN¥1.85 Billion | ▼ -5.8 pp |
| 2023 | -5.2% | CN¥-277.28 Million | CN¥5.35 Billion | CN¥1.53 Billion | CN¥1.80 Billion | ▲ +2.3 pp |
| 2022 | -7.5% | CN¥-371.95 Million | CN¥4.96 Billion | CN¥1.73 Billion | CN¥2.10 Billion | ▼ -23.8 pp |
| 2021 | 16.3% | CN¥765.08 Million | CN¥4.69 Billion | CN¥1.65 Billion | CN¥888.86 Million | ▼ -17.6 pp |
| 2020 | 33.9% | CN¥1.40 Billion | CN¥4.14 Billion | CN¥1.85 Billion | CN¥443.05 Million | ▲ +30.4 pp |
| 2019 | 3.5% | CN¥87.04 Million | CN¥2.47 Billion | CN¥792.24 Million | CN¥705.20 Million | ▲ +11.4 pp |
| 2018 | -7.9% | CN¥-176.35 Million | CN¥2.24 Billion | CN¥574.76 Million | CN¥751.11 Million | ▼ -7.3 pp |
| 2017 | -0.5% | CN¥-10.66 Million | CN¥2.07 Billion | CN¥506.53 Million | CN¥517.19 Million | ▼ -57.4 pp |
| 2016 | 56.9% | CN¥1.10 Billion | CN¥1.93 Billion | CN¥1.30 Billion | CN¥205.42 Million | ▲ +9.7 pp |
| 2015 | 47.2% | CN¥421.84 Million | CN¥893.95 Million | CN¥560.21 Million | CN¥138.37 Million | ▲ +15.0 pp |
| 2014 | 32.1% | CN¥174.57 Million | CN¥543.03 Million | CN¥261.51 Million | CN¥86.94 Million | ▼ -20.0 pp |
| 2013 | 52.1% | CN¥166.30 Million | CN¥319.10 Million | CN¥222.98 Million | CN¥56.68 Million | ▲ +56.3 pp |
| 2012 | -4.2% | CN¥-7.23 Million | CN¥172.56 Million | CN¥63.78 Million | CN¥71.02 Million | ▲ +147.1 pp |
| 2011 | -151.3% | CN¥-79.08 Million | CN¥52.28 Million | CN¥40.22 Million | CN¥119.30 Million | — |